



## **Biomedical Research Advisory Council**

William G. "Bill" Bankhead Jr., and David Coley Cancer Research Program

James and Esther King Biomedical Research Program

Live Like Bella Pediatric Cancer Research Initiative

---

### **Fiscal Year 2024-2025 Funding Opportunity Announcement**

#### **ADDENDUM II**

## Changes to the FY 2024-2025 Funding Opportunity Announcement:

**Page 6: Correction – revises the number of research priorities to original seven.**

**Page 8: Correction – Deletes Emerging Therapeutics and Technologies.**

**Page 9: Adds Emerging Therapeutics and Technologies as a Mechanism of Support to the table with maximum amount and maximum duration.**

### 3. Mechanisms of Support

<b>Bankhead-Coley/James and Esther King Research Programs</b>		
<b>Grant Mechanism</b>	<b>Maximum Amount</b> (Including direct and indirect costs)	<b>Maximum Duration</b>
Discovery Science	\$600,000	36 Months
High-Risk, High-Reward Discovery Science	\$300,000	36 Months
Research Infrastructure	\$1,500,000	36 Months
Clinical Trials/Socio-behavioral Interventions	\$1,500,000	48 Months
High-Risk, High- Reward Clinical Research	\$750,000	48 Months
Bridge	\$100,000	6 months
Equipment	\$100,000	12 months
Non-typical Clinical Trials/Socio-behavioral Research	\$250,000	36 months
New Investigator Research (NIR)	\$300,000	36 months
Emerging Therapeutics and Technologies	\$600,000	36 months
<b>Live Like Bella Pediatric Cancer Research Program</b>		
<b>Grant Mechanism</b>	<b>Maximum Amount</b> (Including direct and indirect costs)	<b>Maximum Duration</b>
Multicenter ClinicalTrials	\$900,000	48 months
High-Risk, High-Reward Clinical Trials	\$300,000	48 months
Discovery Science	\$250,000	36 months
High-Risk, High- Reward Discovery Science	\$125,000	36 months

Bridge	\$100,000	6 months
Equipment	\$100,000	12 months
Non-Typical Clinical Trials/ Socio-behavioral Research	\$250,000	36 months
New Investigator Research (NIR)	\$300,000	36 months
Emerging Therapeutics and Technologies	\$600,000	36 months

**Page 13. Revision – Moves Description from Research Priorities to Mechanism of Support  
Emerging Therapeutics and Technologies**

This funding mechanism supports research on emerging therapeutics and technologies used in the diagnosis and treatment of cancer and tobacco-related diseases. Examples include but are not limited to personalized/precision medicine therapies, immunotherapy, gene therapy, repurposing of previously used medications, use of artificial intelligence (AI) in diagnosis and treatment and comparative effectiveness trials of emerging treatments. Studies focused on innovations in diagnosis and treat of cancer and tobacco-related morbidities (James & Esther King) also fall under this mechanism.